Results 41 to 50 of about 6,610 (196)
Clinical Epidemiology, 2015 Ann Haerskjold,1,2 Lonny Henriksen,2 Susanne Way,1 Mikkel Malham,3 Jesper Hallas,4 Lars Pedersen,5 Lone Graff Stensballe1 1The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Research Unit Women&#
Haerskjold A +6 more
doaj
Pediatric Pulmonology, Volume 61, Issue 10, October 2026.ABSTRACT Objectives Nirsevimab was approved in Europe in 2022 for respiratory syncytial virus (RSV) prevention. In October 2023, Catalonia (Spain) launched a universal immunization program for infants under 6 months during their first RSV season. This study aims to assess the characteristics of patients admitted with bronchiolitis following nirsevimab ...
Marta Agüera +12 more
wiley +1 more source
Passive immunisation of preterm infants with palivizumab against RSV infection
Palivizumab is a monocloncal antibody used for prevention of respiratory syncytial virus infection. This study reviews the literature regarding evidence of efficacy, safety and cost-effectiveness.
Harkensee C +3 more
core +4 more sources
International Journal of Pediatrics, 2014 Infection with respiratory syncytial virus (RSV) is one of the major causes globally of childhood respiratory morbidity and hospitalization. Palivizumab, a humanized monoclonal antibody, has been recommended for high risk infants to prevent severe RSV ...
Nusrat Homaira +3 more
doaj +1 more source
BMC Pediatrics, 2019 Background Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing
Roseane Porfírio de Souza +3 more
doaj +1 more source
Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.The classical herbal formula Qianjinweijingtang in both decoction and granule forms, exhibits anti‐RSV activity. Isoliquiritigenin, quercetin, and gallic acid are identified as key active compounds. The mechanism involves interfering with viral entry and downregulating HIF‐1α and inflammatory responses, positioning the granule formulation as a ...
Chu‐Yi Liao +11 more
wiley +1 more source
, 2015 Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab
Argun, Mustafa +15 more
core +1 more source
Palivizumab: A debate about funding
Journal of Paediatrics and Child Health, 2010 AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic +2 more
openaire +3 more sources
ChemMedChem, Volume 21, Issue 15, 14 August 2026.Temporins, among antimicrobial peptides, are short frog‐derived molecules with potent antibacterial activity. This review highlights chemical optimization strategies applied to temporins A–L, showing how sequence tuning modulates structure, stability, and selectivity, enabling improved activity against resistant pathogens.
Ida Boccino +2 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Respiratory viral infections, particularly Respiratory Syncytial Virus (RSV) and influenza, are major causes of pediatric morbidity, hospitalization, and healthcare strain during winter seasons. This study aims to evaluate the clinical and epidemiological burden of RSV and influenza in pediatric patients and assess associated ...
Shafiqa Alsharif
wiley +1 more source